The “classic” endocannabinoid (eCB) system includes the cannabinoid receptors CB1 and CB2, the eCB ligands anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their metabolic enzymes. An emerging literature documents the “eCB deficiency syndrome” as an etiology in migraine, fibromyalgia, irritable bowel syndrome, psychological disorders, and other conditions. We performed a systematic review of clinical interventions that enhance the eCB system—ways to upregulate cannabinoid receptors, increase ligand synthesis, or inhibit ligand degradation.
Oral Cannabidiol Prevents Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury
CBD Versus Nicotine
CBD may help the heart, inflammation and more…
In this study, we have investigated the effects of cannabidiol (CBD) on myocardial dysfunction, inflammation, oxidative/nitrosative stress, cell death and interrelated signaling pathways, using a…
Non-psychoactive Cannabinoid May Enable Drug Addiction Recovery
An animal study finds that cannabidiol (CBD), a non-psychoactive chemical found in marijuana, may help reduce the risk of drug and alcohol relapse. The research, conducted by the Scripps Research Institute, was funded by the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, both part of the National Institutes of Health.